1 Broadway # 14, Cambridge, MA 02142
Basically, it’s an area of research focused on the connection between cancer and metabolic hormone dysfunction (which is typical in overweight and obese people). Before getting into the details, though, let’s take a step back.
Obesity rates are on the rise in the United States and around the world. Besides increasing the incidence of heart disease, diabetes and metabolic dysfunction, this trend puts people at greater risk of both getting cancer and dying from it. As reported in the Journal of Clinical Oncology:
“Obesity is associated with worsened prognosis after cancer diagnosis and also negatively affects the delivery of systemic therapy, contributes to morbidity of cancer treatment, and may raise the risk of second malignancies and comorbidities.”
Obesity is characterized by excess adipose (or fat) tissue. Excess visceral adipose tissue (belly fat) is common in overweight and obese patients, and releases a variety of hormones that are stimulative to cancer. Over time, this fat depot can become inflamed, leading to systemic insulin resistance and the overproduction of insulin. This combination of events creates an environment that actively promotes tumor growth and metastasis.
These “metabolically sensitive” tumors comprise about 20 percent of cancer cases in the United States and account for over 80,000 deaths from cancer per year. These patients have higher cancer mortality rates than their metabolically normal counterparts. Currently, no novel treatments target this population.
Today, there are no therapies that specifically address the myriad factors that accelerate tumor growth in overweight and obese patients with cancer.
SynDevRx is filling that gap, thus giving hope to the thousands of patients for whom traditional treatments wither don’t work at all or only work for a short time. We believe that by correcting the underlying metabolic dysfunction, SDX-7320 can reduce the tumor-stimulating hormones and inflammation while also directly treating the tumor in our target patient population. This hypothesis — which we’re exploring through clinical trials — is guiding the development of our lead compound.
We look forward to meeting the challenges of bringing metabo-oncology products to the market and to improving clinical outcomes for the millions of cancer patients with underlying metabolic hormone dysfunction worldwide.